InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...
LEO Pharma and Reig Jofre have entered into a partnership aimed at improving access to LEO’s psoriasis treatment in Europe.
For example, in studies of people using Cosentyx for plaque psoriasis ... treatment, talk with your doctor. They can help you understand what to expect and can recommend the best approach for ...
for the treatment of moderate-to-severe plaque psoriasis in China. This is a multicenter, randomized, double-blinded, placebo-controlled Phase III clinical study, designed to evaluate the efficacy ...
Efficacy and Safety of a Highly Selective Oral TYK2 Inhibitor, ICP-488, in Patients with Moderate-to-Severe Plaque Psoriasis ... and commercializing first-in-class and/or best-in-class drugs for the ...
Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...
First for Women on MSN24d
La La Anthony on Her Plaque Psoriasis: ‘It Doesn't Have To Hold You Back'"More than six million people in the U.S. live with plaque psoriasis. So I'm definitely not alone in this journey, and I just ...
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Late-breaking Oral Presentation Efficacy and Safety of a Highly Selective Oral TYK2 Inhibitor, ICP-488, in Patients with Moderate-to-Severe Plaque Psoriasis ... best-in-class drugs for the ...
Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...
Therapies targeting IL-23 have demonstrated good efficacy for moderate/severe plaque psoriasis and have become a treatment staple ... to patients who achieved the best results showed that 33% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback